Competing interests
M.S.v.d.H. has received institutional funding from Bristol Myers Squibb to finance the INDIBLADE trial. C.H., S.K.C., S.S. and A.C.E. are all full-time employee at Natera, Inc. with stocks or options to own stocks in the company. No other author received financial support for the work reported in this paper. No medical writers were involved in drafting the manuscript. B.W.G.v.R. has received consulting fees from Cepheid and Astellas (institutional). L.S.M. received consulting fees from Johnson & Johnson and Merck (institutional). T.N.B. makes use of free-to-use server and software for research purposes from Siemens. J.M.d.F. has an advisory role for Merck and Janssen (institutional). J.C.K.v.d.M. received research support from Bayer (institutional) and received consultancy fees from Merck/Merck Sharp & Dohme, IPSEN, Jansen, Bayer, Novartis and AstraZeneca (institutional). J.L.B. received consulting fees from Bristol Myers Squibb, Janssen, AstraZeneca, Merck AG/Pfizer, Merck Sharp & Dohme, Bayer and Ismar Healthcare (institutional) and received speaker’s fees from Springer Media, Congress Care and NLC Health (personal). R.P.M. has an advisory role for Astellas, Merck and Bristol Myers Squibb (institutional) and received research support from Merck, Janssen-Cilag, Astellas and Gilead Sciences Netherlands (institutional). D.G.J.R. has an advisory role for MSD Oncology, Pfizer, Astellas, AstraZeneca, Johnson & Johnson, Merck and Gilead Sciences Netherlands (institutional) and has received research support from Merck (institutional). B.B.M.S. has an advisory role for AstraZeneca, Bristol Myers Squibb, MDS, IPSEN, Merck, Astellas and Pfizer (institutional) and has received research support from AstraZeneca, Bristol Myers Squibb, MDS, IPSEN, Merck, Astellas and Pfizer (institutional). M.S.v.d.H. has received consulting fees from Astellas, AstraZeneca, Bristol Myers Squibb, MSD Oncology, Pfizer/Seagen, Johnson & Johnson and Daiichi-Sankyo (institutional); has received research support from Bristol Myers Squibb, Roche, AstraZeneca, Seagen, 4SC and MSD Oncology (institutional); and has received travel expenses paid by Bristol Myers Squibb (institutional). All other authors have nothing to disclose.